Latest Breaking News On - Yonsei cancer center - Page 5 : comparemela.com

Repotrectinib Induces Durable Responses in ROS1+ NSCLC Subsets

Treatment with repotrectinib in patients with ROS1-positive non–small cell lung cancer, specifically those who were tyrosine kinase inhibitor-naïve or -pretreated, continued to demonstrate durable clinical activity, as well as durable intracranial responses.

Joseph fioreByoung chul choYonsei university college of medicineBristol myers squibbLung cancer center at yonseiChul choMedical oncologyYonsei cancer centerYonsei university collegeLung cancer centerBlinded independent central reviewPrescription drug user fee actWorld conference on lung cancerIaslc world conference on lung cancerLung cancerNon small cell lung cancer

RaySearch Laboratories : Interim report January 1

/PRNewswire/ SECOND QUARTER (APRIL-JUNE 2023) Order intake SEK 239.2 M (212.5) Net sales SEK 239.5 M (160.2) Operating profit SEK 18.2 M (-19.5) Profit.

United statesUnited kingdomSouth koreaAnnika blondeau henrikssonVarian truebeamHenrik bergentoftCyberknife at lausanne university hospitalUniversity medical center groningenYork university langone hospitalAustralian bragg centerYonsei cancer centerCancer centerBragg centerProton therapyWest florida protonBlondeau henriksson

Data Show Durable Efficacy With Repotrectinib for Locally Advanced or Metastatic ROS1-Positive NSCLC

Based on results from a trial of repotrectinib in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer, the FDA accepted the New Drug Application and set a Prescription Drug User Fee Act goal date of November 27, 2023.

Joseph fioreByoung chul choYonsei university college of medicineBristol myers squibbYonsei cancer centerInternational associationLung cancerNew drug applicationPriority reviewPrescription drug user fee actYonsei university college

Bristol-Myers Squibb (BMY) Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive NSCLC

Bristol-Myers Squibb (BMY) Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive NSCLC
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Joseph fioreByoung chul choBristol myers squibbYonsei cancer centerCancer laboratoryDrug administrationBristol myers squibb companyYonsei university college of medicineLung cancerInternational associationNew drug applicationPriority reviewPrescription drug user fee actBlinded independent central reviewYonsei university collegeBristol myers

Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

Repotrectinib continued to demonstrate high response rates and durable responses, including robust intracranial responses, in patients with ROS1-positive locally advanced or metastatic non-small cell. -Today at 10:20 am- MarketScreener

Joseph fioreByoung chul choBristol myers squibbYonsei cancer centerDrug administrationCancer laboratoryBristol myers squibb companyYonsei university college of medicineExchange commissionLung cancerInternational associationNew drug applicationPriority reviewPrescription drug user fee actBlinded independent central reviewYonsei university college